Cargando…
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603163/ https://www.ncbi.nlm.nih.gov/pubmed/28923081 http://dx.doi.org/10.1186/s13045-017-0518-8 |
| _version_ | 1783264688400760832 |
|---|---|
| author | Foss, Francine Horwitz, Steven Pro, Barbara Miles Prince, H. Sokol, Lubomir Balser, Barbara Wolfson, Julie Coiffier, Bertrand |
| author_facet | Foss, Francine Horwitz, Steven Pro, Barbara Miles Prince, H. Sokol, Lubomir Balser, Barbara Wolfson, Julie Coiffier, Bertrand |
| author_sort | Foss, Francine |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5603163 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56031632017-09-21 Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial Foss, Francine Horwitz, Steven Pro, Barbara Miles Prince, H. Sokol, Lubomir Balser, Barbara Wolfson, Julie Coiffier, Bertrand J Hematol Oncol Erratum BioMed Central 2017-09-18 /pmc/articles/PMC5603163/ /pubmed/28923081 http://dx.doi.org/10.1186/s13045-017-0518-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Erratum Foss, Francine Horwitz, Steven Pro, Barbara Miles Prince, H. Sokol, Lubomir Balser, Barbara Wolfson, Julie Coiffier, Bertrand Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_full | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_fullStr | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_full_unstemmed | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_short | Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| title_sort | erratum to: romidepsin for the treatment of relapsed/refractory peripheral t cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603163/ https://www.ncbi.nlm.nih.gov/pubmed/28923081 http://dx.doi.org/10.1186/s13045-017-0518-8 |
| work_keys_str_mv | AT fossfrancine erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT horwitzsteven erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT probarbara erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT milesprinceh erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT sokollubomir erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT balserbarbara erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT wolfsonjulie erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial AT coiffierbertrand erratumtoromidepsinforthetreatmentofrelapsedrefractoryperipheraltcelllymphomaprolongedstablediseaseprovidesclinicalbenefitsforpatientsinthepivotaltrial |